Company intelligence / Profile preview

Veronvy

California, United States

Ownership: Private
Development stage: Other

Overview

Veronvy Drops are marketed with claims of significant weight loss, improved metabolic health, appetite suppression, and blood sugar regulation, reportedly using semaglutide and other natural ingredients. These claims lack substantiation by peer-reviewed clinical data and have received FDA warning letters for selling unapproved new drugs and misbranding products.

Therapeutic areas: Endocrinology
Modalities: Small moleculeNatural product
Industry: Biotech

Beyond the preview

Go deeper on Veronvy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Veronvy.

Explore the full profile